Benign prostatic hypertrophy (BPH) medication refers to drugs used to treat benign prostatic hypertrophy. BPH is a common prostate disease, especially in older men, characterized by an enlarged prostate that compresses the urethra, causing symptoms such as dysuria, frequent urination, and urgency.
The global Benign Prostatic Hypertrophy Medication market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淏enign Prostatic Hypertrophy Medication Industry Forecast鈥� looks at past sales and reviews total world Benign Prostatic Hypertrophy Medication sales in 2023, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hypertrophy Medication sales for 2024 through 2030. With Benign Prostatic Hypertrophy Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hypertrophy Medication industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hypertrophy Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hypertrophy Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Benign Prostatic Hypertrophy Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hypertrophy Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hypertrophy Medication.
United States market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Benign Prostatic Hypertrophy Medication players cover Zhongshan Kekekang Pharmaceutical Co., Ltd., Hunan Shentaichun Pharmaceutical Co., Ltd., Shanghai Abbott Pharmaceutical Co., Ltd., Suzhou Dongrui Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hypertrophy Medication market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Terazosin
Alfuzosin
Aprilite
Finasteride
Prusatide
Silodosin
Tamsulosin
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Zhongshan Kekekang Pharmaceutical Co., Ltd.
Hunan Shentaichun Pharmaceutical Co., Ltd.
Shanghai Abbott Pharmaceutical Co., Ltd.
Suzhou Dongrui Pharmaceutical Co., Ltd.
China Resources Saike Pharmaceutical Co., Ltd.
Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
Lunan Beite Pharmaceutical Co., Ltd.
Hainan Selike Pharmaceutical Co., Ltd.
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Shanghai Modern Pharmaceutical Co., Ltd.
Nanjing Meirui Pharmaceutical Co., Ltd.
Jiangsu Yongan Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Shandong Langnuo Pharmaceutical Co., Ltd.
Kunming Jida Pharmaceutical Co., Ltd.
Abbott Laboratories
Sanofi
Merck & Co.
Kissei Pharmaceutical
Allergan, Inc
Astellas
Key Questions Addressed in this Report
What is the 10-year outlook for the global Benign Prostatic Hypertrophy Medication market?
What factors are driving Benign Prostatic Hypertrophy Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benign Prostatic Hypertrophy Medication market opportunities vary by end market size?
How does Benign Prostatic Hypertrophy Medication break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Benign Prostatic Hypertrophy Medication by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Benign Prostatic Hypertrophy Medication by Country/Region, 2019, 2023 & 2030
2.2 Benign Prostatic Hypertrophy Medication Segment by Type
2.2.1 Terazosin
2.2.2 Alfuzosin
2.2.3 Aprilite
2.2.4 Finasteride
2.2.5 Prusatide
2.2.6 Silodosin
2.2.7 Tamsulosin
2.3 Benign Prostatic Hypertrophy Medication Sales by Type
2.3.1 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2019-2024)
2.3.2 Global Benign Prostatic Hypertrophy Medication Revenue and Market Share by Type (2019-2024)
2.3.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Type (2019-2024)
2.4 Benign Prostatic Hypertrophy Medication Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Benign Prostatic Hypertrophy Medication Sales by Application
2.5.1 Global Benign Prostatic Hypertrophy Medication Sale Market Share by Application (2019-2024)
2.5.2 Global Benign Prostatic Hypertrophy Medication Revenue and Market Share by Application (2019-2024)
2.5.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Benign Prostatic Hypertrophy Medication Breakdown Data by Company
3.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Company (2019-2024)
3.1.2 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Company (2019-2024)
3.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Company (2019-2024)
3.2.1 Global Benign Prostatic Hypertrophy Medication Revenue by Company (2019-2024)
3.2.2 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company (2019-2024)
3.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hypertrophy Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hypertrophy Medication Product Location Distribution
3.4.2 Players Benign Prostatic Hypertrophy Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Benign Prostatic Hypertrophy Medication by Geographic Region
4.1 World Historic Benign Prostatic Hypertrophy Medication Market Size by Geographic Region (2019-2024)
4.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Benign Prostatic Hypertrophy Medication Market Size by Country/Region (2019-2024)
4.2.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Country/Region (2019-2024)
4.2.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Country/Region (2019-2024)
4.3 Americas Benign Prostatic Hypertrophy Medication Sales Growth
4.4 APAC Benign Prostatic Hypertrophy Medication Sales Growth
4.5 Europe Benign Prostatic Hypertrophy Medication Sales Growth
4.6 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Growth
5 Americas
5.1 Americas Benign Prostatic Hypertrophy Medication Sales by Country
5.1.1 Americas Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
5.1.2 Americas Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
5.2 Americas Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
5.3 Americas Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hypertrophy Medication Sales by Region
6.1.1 APAC Benign Prostatic Hypertrophy Medication Sales by Region (2019-2024)
6.1.2 APAC Benign Prostatic Hypertrophy Medication Revenue by Region (2019-2024)
6.2 APAC Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
6.3 APAC Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Benign Prostatic Hypertrophy Medication by Country
7.1.1 Europe Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
7.1.2 Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
7.2 Europe Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
7.3 Europe Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Benign Prostatic Hypertrophy Medication by Country
8.1.1 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
8.1.2 Middle East & Africa Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
8.2 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
8.3 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hypertrophy Medication
10.3 Manufacturing Process Analysis of Benign Prostatic Hypertrophy Medication
10.4 Industry Chain Structure of Benign Prostatic Hypertrophy Medication
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hypertrophy Medication Distributors
11.3 Benign Prostatic Hypertrophy Medication Customer
12 World Forecast Review for Benign Prostatic Hypertrophy Medication by Geographic Region
12.1 Global Benign Prostatic Hypertrophy Medication Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hypertrophy Medication Forecast by Region (2025-2030)
12.1.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Benign Prostatic Hypertrophy Medication Forecast by Type (2025-2030)
12.7 Global Benign Prostatic Hypertrophy Medication Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Zhongshan Kekekang Pharmaceutical Co., Ltd.
13.1.1 Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
13.1.2 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.1.3 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Zhongshan Kekekang Pharmaceutical Co., Ltd. Main Business Overview
13.1.5 Zhongshan Kekekang Pharmaceutical Co., Ltd. Latest Developments
13.2 Hunan Shentaichun Pharmaceutical Co., Ltd.
13.2.1 Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
13.2.2 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.2.3 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Hunan Shentaichun Pharmaceutical Co., Ltd. Main Business Overview
13.2.5 Hunan Shentaichun Pharmaceutical Co., Ltd. Latest Developments
13.3 Shanghai Abbott Pharmaceutical Co., Ltd.
13.3.1 Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
13.3.2 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.3.3 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Shanghai Abbott Pharmaceutical Co., Ltd. Main Business Overview
13.3.5 Shanghai Abbott Pharmaceutical Co., Ltd. Latest Developments
13.4 Suzhou Dongrui Pharmaceutical Co., Ltd.
13.4.1 Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
13.4.2 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.4.3 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Suzhou Dongrui Pharmaceutical Co., Ltd. Main Business Overview
13.4.5 Suzhou Dongrui Pharmaceutical Co., Ltd. Latest Developments
13.5 China Resources Saike Pharmaceutical Co., Ltd.
13.5.1 China Resources Saike Pharmaceutical Co., Ltd. Company Information
13.5.2 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.5.3 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 China Resources Saike Pharmaceutical Co., Ltd. Main Business Overview
13.5.5 China Resources Saike Pharmaceutical Co., Ltd. Latest Developments
13.6 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
13.6.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
13.6.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.6.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Main Business Overview
13.6.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Latest Developments
13.7 Lunan Beite Pharmaceutical Co., Ltd.
13.7.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
13.7.2 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.7.3 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Lunan Beite Pharmaceutical Co., Ltd. Main Business Overview
13.7.5 Lunan Beite Pharmaceutical Co., Ltd. Latest Developments
13.8 Hainan Selike Pharmaceutical Co., Ltd.
13.8.1 Hainan Selike Pharmaceutical Co., Ltd. Company Information
13.8.2 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.8.3 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hainan Selike Pharmaceutical Co., Ltd. Main Business Overview
13.8.5 Hainan Selike Pharmaceutical Co., Ltd. Latest Developments
13.9 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
13.9.1 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
13.9.2 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.9.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Latest Developments
13.10 Shanghai Modern Pharmaceutical Co., Ltd.
13.10.1 Shanghai Modern Pharmaceutical Co., Ltd. Company Information
13.10.2 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.10.3 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shanghai Modern Pharmaceutical Co., Ltd. Main Business Overview
13.10.5 Shanghai Modern Pharmaceutical Co., Ltd. Latest Developments
13.11 Nanjing Meirui Pharmaceutical Co., Ltd.
13.11.1 Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
13.11.2 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.11.3 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Nanjing Meirui Pharmaceutical Co., Ltd. Main Business Overview
13.11.5 Nanjing Meirui Pharmaceutical Co., Ltd. Latest Developments
13.12 Jiangsu Yongan Pharmaceutical Co., Ltd.
13.12.1 Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
13.12.2 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.12.3 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Jiangsu Yongan Pharmaceutical Co., Ltd. Main Business Overview
13.12.5 Jiangsu Yongan Pharmaceutical Co., Ltd. Latest Developments
13.13 Zhejiang Huahai Pharmaceutical Co., Ltd.
13.13.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
13.13.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.13.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business Overview
13.13.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Latest Developments
13.14 Shandong Langnuo Pharmaceutical Co., Ltd.
13.14.1 Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
13.14.2 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.14.3 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Shandong Langnuo Pharmaceutical Co., Ltd. Main Business Overview
13.14.5 Shandong Langnuo Pharmaceutical Co., Ltd. Latest Developments
13.15 Kunming Jida Pharmaceutical Co., Ltd.
13.15.1 Kunming Jida Pharmaceutical Co., Ltd. Company Information
13.15.2 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.15.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Kunming Jida Pharmaceutical Co., Ltd. Main Business Overview
13.15.5 Kunming Jida Pharmaceutical Co., Ltd. Latest Developments
13.16 Abbott Laboratories
13.16.1 Abbott Laboratories Company Information
13.16.2 Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.16.3 Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Abbott Laboratories Main Business Overview
13.16.5 Abbott Laboratories Latest Developments
13.17 Sanofi
13.17.1 Sanofi Company Information
13.17.2 Sanofi Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.17.3 Sanofi Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Sanofi Main Business Overview
13.17.5 Sanofi Latest Developments
13.18 Merck & Co.
13.18.1 Merck & Co. Company Information
13.18.2 Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.18.3 Merck & Co. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Merck & Co. Main Business Overview
13.18.5 Merck & Co. Latest Developments
13.19 Kissei Pharmaceutical
13.19.1 Kissei Pharmaceutical Company Information
13.19.2 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.19.3 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Kissei Pharmaceutical Main Business Overview
13.19.5 Kissei Pharmaceutical Latest Developments
13.20 Allergan, Inc
13.20.1 Allergan, Inc Company Information
13.20.2 Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.20.3 Allergan, Inc Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Allergan, Inc Main Business Overview
13.20.5 Allergan, Inc Latest Developments
13.21 Astellas
13.21.1 Astellas Company Information
13.21.2 Astellas Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.21.3 Astellas Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Astellas Main Business Overview
13.21.5 Astellas Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
